LAG3 and melanoma: In a phase 2 trial of patients with resectable clinical stage III or oligometastatic stage IV melanoma, neoadjuvant relatlimab, an anti-LAG-3 monoclonal antibody, combined with nivolumab and adjuvant combination therapy demonstrated a pRR of 70.0% and an MPR of 63%, with no grade 3 or higher immune-related adverse events during neoadjuvant treatment10.